A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT05664243 by In8bio Inc., with 4 participants enrolled, started 2023-09-08 and due to reach its primary completion in 2025-12. Interventions recorded: Autologous genetically modified gamma-delta T cells and Allogeneic genetically modified gamma-delta T cells.